Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 20 for:    view2 macular degeneration
Previous Study | Return to List | Next Study

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)

This study has been completed.
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00637377
First received: March 12, 2008
Last updated: April 25, 2014
Last verified: April 2014

March 12, 2008
April 25, 2014
April 2008
September 2010   (final data collection date for primary outcome measure)
Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) [ Time Frame: At week 52 ] [ Designated as safety issue: No ]

Maintenance of vision was defined as a loss of < 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.

Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.

The proportion of subjects who maintain vision at Week 52, where a subject is classified as maintaining vision if the subject has lost fewer than 15 letters on the ETDRS chart compared to baseline (ie, prevention of moderate vision loss) [ Time Frame: Week 52 ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00637377 on ClinicalTrials.gov Archive Site
  • Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]
    Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
  • Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF [ Time Frame: At week 52 ] [ Designated as safety issue: No ]

    Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.

    Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.

  • Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]
    The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).
  • Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF [ Time Frame: Baseline and at week 52 ] [ Designated as safety issue: No ]
    CNV area values measured in square millimeters; lower values represent better outcomes.
  • Mean change from baseline in BCVA as measured by ETDRS letter score at Week 52 [ Time Frame: week 52 ] [ Designated as safety issue: Yes ]
  • The proportion of subjects who gain at least 15 letters of vision at Week 52 [ Time Frame: week 52 ] [ Designated as safety issue: No ]
  • Mean change from baseline in total NEI VFQ-25 score at Week 52 [ Time Frame: week 52 ] [ Designated as safety issue: No ]
  • Mean change from baseline in CNV area at Week 52 [ Time Frame: week 52 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD)

This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.

Data of this trial ("VIEW 2") was pooled with data of a sister trial ("VIEW 1", NCT00509795), and an integrated analyses of the combined data was performed.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Macular Degeneration
  • Drug: Ranibizumab
    Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
  • Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
    Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
  • Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
    Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
  • Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
    Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
  • Active Comparator: Ranibizumab 0.5mg Q4
    Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
    Intervention: Drug: Ranibizumab
  • Experimental: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4
    Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
    Intervention: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
  • Experimental: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4
    Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
    Intervention: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
  • Experimental: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
    Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
    Intervention: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1240
August 2011
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed informed consent.
  • Men and women >/=50 years of age.
  • Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by Fluorescein angiography (FA) in the study eye.
  • ETDRS Best-Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters.
  • Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
  • Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and willing to sign the informed consent form.

Exclusion Criteria:

  • Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins.
  • Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye.
  • Any prior treatment with anti-VEGF agents in the study eye.
  • Total lesion size >12 disc areas (30.5 mm, including blood, scars and neovascularization) as assessed by FA in the study eye.
  • Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye (if the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV).
  • Scar or fibrosis making up >50% of the total lesion in the study eye.
  • Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
  • Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
  • History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
  • Presence of other causes of CNV in the study eye.
  • Prior vitrectomy in the study eye.
  • History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
  • Any history of macular hole of stage 2 and above in the study eye.
  • Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of Day 1, as long as it is unlikely to interfere with the injection.
  • History or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than AMD in either eye.
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Austria,   Belgium,   Brazil,   Colombia,   Czech Republic,   France,   Germany,   Hungary,   India,   Israel,   Italy,   Japan,   Korea, Republic of,   Latvia,   Mexico,   Netherlands,   Poland,   Portugal,   Singapore,   Slovakia,   Spain,   Sweden,   Switzerland,   United Kingdom
 
NCT00637377
91689, 2007-000583-25
Yes
Bayer
Bayer
Regeneron Pharmaceuticals
Study Director: Bayer Study Director Bayer
Bayer
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP